Literature DB >> 21773754

Usefulness of a break-apart FISH assay in the diagnosis of Xp11.2 translocation renal cell carcinoma.

Soo Hee Kim1, Yoomi Choi, Hae Yeon Jeong, Kyoungbun Lee, Ji Youn Chae, Kyung Chul Moon.   

Abstract

Xp11.2 translocation renal cell carcinoma (RCC) is a rare subtype of RCC predominantly reported in young patients. It results from gene fusions between the transcription factor E3 (TFE3) gene, which is located on chromosome Xp11.2, and various fusion partners. Recently, a dual color, break-apart fluorescence in situ hybridization (FISH) assay to detect Xp11.2 translocation was reported. We performed this study to evaluate the usefulness of the FISH assay in the diagnosis of Xp11.2 translocation RCC using a commercially available TFE3 break-apart probe. We immunohistochemically analyzed TFE3 nuclear expression in 809 cases of RCCs using 14 tissue microarray blocks and selected nine cases those showed moderate to strong positive nuclear immunoreactivity for TFE3. The extent of TFE3 nuclear expression was variable. The TFE3 FISH assay was performed in these 9 selected cases and 44 negative control cases. Only four out of nine selected cases showed the TFE3 break-apart signal. TFE3 FISH-positive cases mainly showed diffuse and strong TFE3 immunopositivity, but one case revealed focal and moderate TFE3 staining. On the contrary, TFE3 FISH-negative cases mainly revealed focal and moderate TFE3 immunoreactivity, however, one FISH-negative case revealed diffuse and strong TFE3 nuclear immunopositivity. All negative control cases revealed normal TFE3 FISH results. Our results reveal that TFE3 immunohistochemistry can show false-positive results, and that the TFE3 break-apart FISH assay is a useful complementary method for confirming the diagnosis of Xp11.2 translocation RCC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21773754     DOI: 10.1007/s00428-011-1127-5

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  25 in total

1.  Fusion of a novel gene, RCC17, to the TFE3 gene in t(X;17)(p11.2;q25.3)-bearing papillary renal cell carcinomas.

Authors:  P Heimann; H El Housni; G Ogur; M A Weterman; E M Petty; G Vassart
Journal:  Cancer Res       Date:  2001-05-15       Impact factor: 12.701

2.  A distinctive subset of PEComas harbors TFE3 gene fusions.

Authors:  Pedram Argani; Sebastian Aulmann; Peter B Illei; George J Netto; Jae Ro; Hyun-yee Cho; Snjezana Dogan; Marc Ladanyi; Guido Martignoni; John R Goldblum; Sharon W Weiss
Journal:  Am J Surg Pathol       Date:  2010-10       Impact factor: 6.394

3.  Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents.

Authors:  P Argani; C R Antonescu; P B Illei; M Y Lui; C F Timmons; R Newbury; V E Reuter; A J Garvin; A R Perez-Atayde; J A Fletcher; J B Beckwith; J A Bridge; M Ladanyi
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

4.  Adult-onset renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusion with smooth muscle stroma and abnormal vessels.

Authors:  Naoto Kuroda; Masato Tamura; Yukichi Tanaka; Ondrej Hes; Michal Michal; Kaori Inoue; Masahiko Ohara; Keiko Mizuno; Gang-Hong Lee
Journal:  Pathol Int       Date:  2009-07       Impact factor: 2.534

Review 5.  Translocation carcinomas of the kidney.

Authors:  Pedram Argani; Marc Ladanyi
Journal:  Clin Lab Med       Date:  2005-06       Impact factor: 1.935

6.  PRCC-TFE3 renal carcinomas: morphologic, immunohistochemical, ultrastructural, and molecular analysis of an entity associated with the t(X;1)(p11.2;q21).

Authors:  Pedram Argani; Cristina R Antonescu; Jérôme Couturier; Jean-Christophe Fournet; Raf Sciot; Maria Debiec-Rychter; Brian Hutchinson; Victor E Reuter; Lilliane Boccon-Gibod; Charles Timmons; Naiel Hafez; Marc Ladanyi
Journal:  Am J Surg Pathol       Date:  2002-12       Impact factor: 6.394

7.  Xp11 translocation carcinoma of the kidney presenting with multilocular cystic renal cell carcinoma-like features.

Authors:  Sueli Suzigan; Ricardo Drut; Paulo Faria; Pedram Argani; Angelo M De Marzo; Rui Nogueira Barbosa; Eliseu Roberto Mello Denadai; Júlio Martins-Filho; Rubens Carlos Martucci; Tufik Bauab
Journal:  Int J Surg Pathol       Date:  2007-04       Impact factor: 1.271

8.  Mapping the X chromosome breakpoint in two papillary renal cell carcinoma cell lines with a t(X;1)(p11.2;q21.2) and the first report of a female case.

Authors:  J M Shipley; S Birdsall; J Clark; J Crew; S Gill; M Linehan; J Gnarra; S Fisher; I W Craig; C S Cooper
Journal:  Cytogenet Cell Genet       Date:  1995

9.  Xp11.2 translocation renal cell carcinoma with very aggressive course in five adults.

Authors:  Paul N Meyer; Joseph I Clark; Robert C Flanigan; Maria M Picken
Journal:  Am J Clin Pathol       Date:  2007-07       Impact factor: 2.493

10.  Xp11.2 translocation renal cell carcinoma occurring during pregnancy with a novel translocation involving chromosome 19: a case report with review of the literature.

Authors:  Henry B Armah; Anil V Parwani; Urvashi Surti; Sheldon I Bastacky
Journal:  Diagn Pathol       Date:  2009-05-18       Impact factor: 2.644

View more
  16 in total

1.  TMED6-COG8 is a novel molecular marker of TFE3 translocation renal cell carcinoma.

Authors:  Yongcan Xu; Qiu Rao; Qiuyuan Xia; Shanshan Shi; Qunli Shi; Henghui Ma; Zhenfeng Lu; Hui Chen; Xiaojun Zhou
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

2.  [Histopathology of renal cell carcinoma].

Authors:  C G Stöhr; K Amann; A Hartmann
Journal:  Urologe A       Date:  2013-07       Impact factor: 0.639

3.  Identification of molecular tumor markers in renal cell carcinomas with TFE3 protein expression by RNA sequencing.

Authors:  Dorothee Pflueger; Andrea Sboner; Martina Storz; Jasmine Roth; Eva Compérat; Elisabeth Bruder; Mark A Rubin; Peter Schraml; Holger Moch
Journal:  Neoplasia       Date:  2013-11       Impact factor: 5.715

Review 4.  Interpretation of needle biopsies of the kidney for investigation of renal masses.

Authors:  Benoît Lhermitte; Laurence de Leval
Journal:  Virchows Arch       Date:  2012-06-08       Impact factor: 4.064

5.  TFE3 and TFEB-rearranged renal cell carcinomas: an immunohistochemical panel to differentiate from common renal cell neoplasms.

Authors:  Anna Caliò; Stefano Marletta; Matteo Brunelli; Serena Pedron; Sofia Canete Portillo; Diego Segala; Elena Bariani; Stefano Gobbo; George Netto; Guido Martignoni
Journal:  Virchows Arch       Date:  2022-08-18       Impact factor: 4.535

6.  Xp11 translocation renal cell carcinoma in adults: a clinicopathological and comparative genomic hybridization study.

Authors:  Hong Zou; Xueling Kang; Li-Juan Pang; Wenhao Hu; Jin Zhao; Yan Qi; Jianming Hu; Chunxia Liu; Hongan Li; Weihua Liang; Xianglin Yuan; Feng Li
Journal:  Int J Clin Exp Pathol       Date:  2013-12-15

Review 7.  Molecular genetics and immunohistochemistry characterization of uncommon and recently described renal cell carcinomas.

Authors:  Qiu Rao; Qiu-Yuan Xia; Liang Cheng; Xiao-Jun Zhou
Journal:  Chin J Cancer Res       Date:  2016-02       Impact factor: 5.087

8.  Renal cell carcinoma in tuberous sclerosis complex.

Authors:  Ping Yang; Kristine M Cornejo; Peter M Sadow; Liang Cheng; Mingsheng Wang; Yu Xiao; Zhong Jiang; Esther Oliva; Sergiusz Jozwiak; Robert L Nussbaum; Adam S Feldman; Elahna Paul; Elizabeth A Thiele; Jane J Yu; Elizabeth P Henske; David J Kwiatkowski; Robert H Young; Chin-Lee Wu
Journal:  Am J Surg Pathol       Date:  2014-07       Impact factor: 6.394

9.  Xp11.2 translocation renal cell carcinomas in young adults.

Authors:  Linfeng Xu; Rong Yang; Weidong Gan; Xiancheng Chen; Xuefeng Qiu; Kai Fu; Jin Huang; Guancheng Zhu; Hongqian Guo
Journal:  BMC Urol       Date:  2015-07-01       Impact factor: 2.264

10.  ALK-Positive Renal Cell Carcinoma in a Large Series of Consecutively Resected Korean Renal Cell Carcinoma Patients.

Authors:  Cheol Lee; Jeong Whan Park; Ja Hee Suh; Kyung Han Nam; Kyung Chul Moon
Journal:  Korean J Pathol       Date:  2013-10-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.